BUZUD, Fosun Trade Medical Devices launches two-in-one blood glucose and uric acid tester

Source: BUZUD, Fosun Trade Medical Devices. The Safe AQ UG Blood Glucose and Uric Acid Monitoring System enables uric acid levels as well as blood glucose levels to be tested at home.

BUZUD, Fosun Trade Medical Devices, a manufacturer of medical appliances, has made available BUZUD’s Safe AQ UG Blood Glucose and Uric Acid Monitoring System. This dual function test system enables users to measure blood sugar and uric acid levels conveniently and accurately.*

While testing blood glucose levels can commonly be done at home, the conventional way to test uric acid levels is to send a urine or blood sample for testing to a laboratory. This process is costly and it can take up to three days to receive the results.

Certified by government health ministries in many countries, including Singapore’s Health Sciences Authority (HSA), the BUZUD Safe AQ UG Blood Glucose and Uric Acid Monitoring System uses FAD-GDH (flavin adenine dinucleotide-dependent glucose dehydrogenase) technology, coupled with an anti-interference enzyme layer design. This enables more accurate blood glucose tests based on electrochemical glucose measurements without interference from oxygen, blood, ascorbic acid, and other internal and external interference sources in the blood sample.

“People with high levels of blood sugar and/or uric acid often find it challenging to regularly monitor their blood sugar and uric acid levels as it can be a hassle to test quickly and simply,” said Frankie Fan, founder, CEO and CTO of BUZUD, Fosun Trade Medical Devices.

“BUZUD’s Safe AQ UG Blood Glucose and Uric Acid meter is a new generation of bifunctional monitoring system that offers the convenience of testing both blood glucose and uric acid on a single meter, with results detected within 30 seconds.”

According to the World Health Organization, 422 million people worldwide have diabetes and it is one of the leading causes of death in the world. Effectively managing diabetes would depend on patients acting on the results of their blood glucose tests.

And when the kidneys are unable to eliminate uric acid efficiently, causing high uric acid levels, gout as well as permanent bone, joint and tissue damage, kidney disease, and heart disease can occur. Regularly monitoring of uric acid levels is key to effective uric acid management, said the company. When it comes to gout, some 41.2 million people are estimated to have the illness.

The BUZUD Safe AQ UG Blood Glucose and Uric Acid Monitoring System requires a small blood sample to return results at up to 95% accuracy. A lancet is used to prick a finger and a small sample of blood is applied to the relevant test strips. The blood glucose and/or uric acid test strips are then inserted into the Safe AQ UG blood glucose and uric acid meter, after which blood glucose test results will be shown within 5 seconds and uric acid test results within 25 seconds. The test strips are then ejected safely with a one-click system.

The system stores 200 of the most recent results (100 blood glucose and 100 uric acid test results) with date and time stamps for easy long-term monitoring.

The Monitoring System includes the following:

• Safe AQ UG blood glucose and uric acid meter

• Safe AQ UG blood glucose test strips

• Safe AQ UG uric acid test strips

• Blood glucose control solution

• Uric acid control solution

Details:

The BUZUD Safe AQ UG Blood Glucose and Uric Acid Monitoring System is now available for purchase in Singapore, Australia, China, Europe, and Malaysia.

In Singapore the new system is available online for S$243.96 at the Buzud.Roffe Lazada Store, or physically at the BUZUD retail store at:

585 North Bridge Road #01-02,

Raffles Hospital,

Singapore 188770

+65 6518 9959

www.buzud.com

*The BUZUD Safe AQ UG Blood Glucose and Uric Acid Monitoring System should not be used for the diagnosis of or screening of diabetes and hyperuricemia (HUA).

Abbott brings Freestyle Libre Pro System for glucose monitoring to India

The prevalence of type II diabetes is increasing in young adults in Asia, according to research from the Asia Diabetes Foundation (ADF). The ADF has funded research* together with Merck showing that 18% of the people recruited into its Joint Asia Diabetes Evaluation (JADE) study from nine Asian countries and territories were under the age of 40 when they were diagnosed with diabetes, a condition called young-onset diabetes.

While Merck offers a drug called Janumet XR to address type II diabetes, Abbott is tackling the treatment of the disease with a wearable that offers doctors more insights into patients' blood glucose levels over the long term.

Source: Abbott website. The FreeStyle Libre System at work. The FreeStyle Libre Pro System is designed to be used by healthcare professionals, rather than by patients themselves.

"India now carries 20% of the global burden of diabetes," said Robert Ford, Senior VP, Diabetes Care, Abbott. "There is an immense need for people in India to better manage their diabetes, enabling them to live healthier lives. Abbott's FreeStyle Libre Pro System is designed to empower doctors in India to help their patients through rich data and actionable insights."

The FreeStyle Libre Pro Flash Glucose Monitoring System consists of a small, round sensor—slightly larger than a 10 rupee coin (the size of a US quarter). A healthcare professional applies the sensor on the back of the patient's upper arm. The sensor is held in place with a self-adhesive pad and remains on the back of the arm for up to 14 days, requiring no patient interaction.

When applied to the skin, the sensor continuously measures glucose in interstitial fluid through a small (5mm long, 0.4mm wide) filament that is inserted just under the skin. It records glucose levels every 15 minutes, capturing up to 1,340 glucose results over 14 days, giving doctors comprehensive data for a complete glycemic profile of their patients. After 14 days, the person returns to the doctor's office, where the doctor uses a FreeStyle Libre Pro reader device to download the glucose results that are stored in the sensor in as quickly as five seconds.

"Diabetes is already at epidemic proportions and there is an urgent need to manage it better," said Dr V Mohan, Director and Chief of Diabetes Research at Madras Diabetes Research Foundation. "Current diabetes monitoring tools are limiting for doctors because they don't reveal a complete picture of the glucose variability that a person goes through during a day. The revolutionary flash glucose monitoring system will be very useful for doctors in getting complete glucose profiles of their patients. This will help us in our clinical decision making as well as in personalising treatment plans for better outcomes."

"Current systems for continuous measurement of glucose are cumbersome and require regular finger-pricking to ensure they are calibrated correctly for accuracy," said Jared Watkin, Divisional VP, Technical Operations, Diabetes Care, Abbott. "Based on insights from our customers, the focus for our design team has been to innovate for these challenges, while also providing affordability. We're proud that FreeStyle Libre Pro System achieves that for people with diabetes."

Abbott's FreeStyle Libre Pro system will be available to doctors in coming weeks in six Indian cities including Mumbai, Delhi, Chennai, Bangalore, Pune and Trivandrum.

According to the International Diabetes Federation, India today has a diabetes population of 65.1 million compared to 50.8 million in 2010**. A recent survey conducted by the Association of Physicians of India (API) and sponsored by Abbott*** showed that 90% of people surveyed with uncontrolled diabetes in India, defined as HbA1c levels higher than 7%, continue to believe that they have control over their glucose levels, despite facts suggesting otherwise. 

The Diabetic Society of Singapore has estimated that over 400,000 people or 11.3% of the population suffer from diabetes, while Singapore's Khoo Teck Puat Hospital has found that two-thirds of its diabetes patients under 30 have the type II form. 

*Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort, The Lancet Diabetes & Endocrinology, e-publication July 2014, print publication December 2014.

**http://www.idf.org/BRIDGES/map/india

***The Abbott Sugar Survey, February 2015